Guardian Asset Advisors LLC Has $862,000 Position in Johnson & Johnson (NYSE:JNJ)

Guardian Asset Advisors LLC reduced its stake in Johnson & Johnson (NYSE:JNJ) by 12.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,961 shares of the company’s stock after selling 885 shares during the period. Guardian Asset Advisors LLC’s holdings in Johnson & Johnson were worth $862,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in JNJ. SFE Investment Counsel raised its holdings in Johnson & Johnson by 12.1% in the 4th quarter. SFE Investment Counsel now owns 28,456 shares of the company’s stock valued at $4,115,000 after buying an additional 3,065 shares during the last quarter. Pathway Financial Advisers LLC raised its holdings in Johnson & Johnson by 0.4% in the 4th quarter. Pathway Financial Advisers LLC now owns 20,138 shares of the company’s stock valued at $2,912,000 after buying an additional 89 shares during the last quarter. Howard Bailey Securities LLC raised its holdings in Johnson & Johnson by 9.0% in the 4th quarter. Howard Bailey Securities LLC now owns 1,406 shares of the company’s stock valued at $203,000 after buying an additional 116 shares during the last quarter. Sawgrass Asset Management LLC raised its holdings in Johnson & Johnson by 66.3% in the 4th quarter. Sawgrass Asset Management LLC now owns 109,395 shares of the company’s stock valued at $15,821,000 after buying an additional 43,598 shares during the last quarter. Finally, Stanley Laman Group Ltd. raised its holdings in Johnson & Johnson by 38.9% in the 4th quarter. Stanley Laman Group Ltd. now owns 2,407 shares of the company’s stock valued at $348,000 after buying an additional 674 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Johnson & Johnson

In other news, Director Mark A. Weinberger bought 1,000 shares of Johnson & Johnson stock in a transaction dated Thursday, December 12th. The stock was purchased at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the purchase, the director now directly owns 1,000 shares in the company, valued at $147,220. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $156.20 on Monday. The firm has a market capitalization of $376.08 billion, a PE ratio of 23.49, a price-to-earnings-growth ratio of 2.46 and a beta of 0.52. The firm has a fifty day simple moving average of $147.87 and a two-hundred day simple moving average of $155.96. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. Johnson & Johnson’s quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.29 EPS. Analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.18%. Johnson & Johnson’s payout ratio is 74.59%.

Analysts Set New Price Targets

JNJ has been the subject of a number of research reports. Citigroup dropped their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Bank of America dropped their price target on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating on the stock in a research report on Thursday, January 23rd. Royal Bank of Canada restated an “outperform” rating and issued a $181.00 price target on shares of Johnson & Johnson in a research report on Thursday, January 23rd. Finally, Wolfe Research started coverage on shares of Johnson & Johnson in a research report on Friday, November 15th. They issued an “outperform” rating and a $190.00 price target on the stock. Nine equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $170.67.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.